GSK: licensing agreement with Chinese company Hansoh
Under the terms of this agreement, GSK will have an exclusive option to pursue the development of HS-20093, as well as its commercialization outside China, Hong Kong, Macao and Taiwan.
GSK, which notes that HS-20093 is currently undergoing Phase I and II clinical trials in China for the treatment of solid tumors, plans to launch a study outside China next year.
In return, the company has agreed to pay Hansoh an upfront payment of $8 million, to which could be added more than $1.5 billion in milestone payments in the event of the project's success, in addition to possible royalties on future sales of the drug.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction